Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?

Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In ...
Hosted on MSN

How Edgewise sweetened its coffers by $1.55 billion, and removed a key overhang

Edgewise TherapeuticsEWTX stock rocketed Monday after pharma giant Servier agreed to buy the biotech's muscular dystrophy business for up to $2.65 billion. The deal includes Edgewise's experimental ...
Yahoo Finance

Assessing Edgewise Therapeutics (EWTX) Valuation After Recent Share Price Momentum

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investing

Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...
The Motley Fool

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period. The ...
Morningstar

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of ...
Nasdaq

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel ...
Investing

Edgewise shares Phase 1 and 2 trial data for heart drug

BOULDER, Colo. - Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease, has announced an upcoming webcast to discuss preliminary data from clinical trials of ...